Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.

MLA

Tanase, Daniela Maria, et al. “Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.” Diagnostics (Basel, Switzerland), vol. 11, no. 11, Nov. 2021. EBSCOhost, https://doi.org/10.3390/diagnostics11112053.

APA

Tanase, D. M., Gosav, E. M., Petrov, D., Jucan, A. E., Lacatusu, C. M., Floria, M., Tarniceriu, C. C., Costea, C. F., Ciocoiu, M., & Rezus, C. (2021). Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Diagnostics (Basel, Switzerland), 11(11). https://doi.org/10.3390/diagnostics11112053

Chicago

Tanase, Daniela Maria, Evelina Maria Gosav, Daniela Petrov, Alina Ecaterina Jucan, Cristina Mihaela Lacatusu, Mariana Floria, Claudia Cristina Tarniceriu, Claudia Florida Costea, Manuela Ciocoiu, and Ciprian Rezus. 2021. “Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.” Diagnostics (Basel, Switzerland) 11 (11). doi:10.3390/diagnostics11112053.